title: Treatment of endometriosis with the GnRH agonist nafarelin acetate.
abstract: Additional details of a multicenter study of nafarelin acetate with particular attention to a unique endometriosis scoring system utilized are reviewed. Additional information regarding the relapse of symptoms of 10 patients treated with nafarelin and danazol during a 6- to 12-month follow-up interval is described. Transient decreases in leukocytes previously reported by other investigators were observed in 3 of 8 patients, but appear to represent a laboratory artifact.
authors.affiliation: Mayo Graduate School of Medicine, Rochester, Minnesota.
authors.forename: L A
authors.initials: LA
authors.lastname: Jacobs
authors.forename: C S
authors.initials: CS
authors.lastname: Field
authors.forename: J L
authors.initials: JL
authors.lastname: Thie
authors.forename: C B
authors.initials: CB
authors.lastname: Coulam
mesh_terms: D000293:Adolescent; D000328:Adult; D003613:Danazol / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D017274:Nafarelin; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D017274:Nafarelin; D007987:Gonadotropin-Releasing Hormone; D003613:Danazol